Discovery Labs

Discovery Labs (DSCO) is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. In early 2013, the company was in need of capital to enable the launch of its recently approved drug, SURFAXIN®, for the prevention or respiratory distress syndrome in premature infants and for development of its pipeline of novel therapies for respiratory critical care.